47 results
PRE 14A
ALGS
Aligos Therapeutics Inc
16 Apr 24
Preliminary proxy
5:27pm
Act of 2002 and Item 406 of Regulation S-K. In addition, we intend to promptly disclose (1) the nature of any substantive amendment to our Code … or persons performing similar functions and (2) the nature of any waiver, including an implicit waiver, from a provision of our code of ethics
SC TO-I
EX-99
ALGS
Aligos Therapeutics Inc
30 Jan 24
Issuer tender offer statement
7:04am
DISCRETIONARY IN NATURE AND IS NOT TO BE CONSIDERED PART OF ANY NORMAL OR EXPECTED COMPENSATION THAT IS OR WOULD BE SUBJECT TO SEVERANCE, RESIGNATION … to the Offer for eligible employees and directors subject to tax in Switzerland. This discussion is general in nature and does not discuss all of the tax
D
ALGS
Aligos Therapeutics Inc
7 Nov 23
$92.15 mm in equity / options / securities to be acquired, sold $92.15 mm, 11 investors
12:03pm
that are the subject of this Form D are "covered securities" for purposes
of NSMIA, whether in all instances or due to the nature of the offering
8-K
EX-4.2
hbv84nv8td7
25 Oct 23
Entry into a Material Definitive Agreement
5:05pm
8-K
EX-10.1
5x9i3mc97 rq884t
25 Oct 23
Entry into a Material Definitive Agreement
5:05pm
CORRESP
h9c ood54
22 Dec 22
Correspondence with SEC
12:00am
UPLOAD
93g73o
8 Dec 22
Letter from SEC
12:00am
S-3
EX-4.4
kfzxz6tdq9ubhk
4 Nov 21
Shelf registration
4:57pm